Cadrenal Therapeutics Inc expected to post a loss of $1.60 a share - Earnings Preview
05/08/2025 12:01
Cadrenal Therapeutics Inc CVKD.OQ CVKD.O is expected to show no change in quarterly revenue when it reports results on August 7 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for Cadrenal Therapeutics Inc is for a loss of $1.60 per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Cadrenal Therapeutics Inc is $32.00, about 72.5% above its last closing price of $8.81 Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -1.13 | -1.64 | -2.09 | Missed | -27.4 |
| Dec. 31 2025 | -1.41 | -1.71 | -2.74 | Missed | -59.9 |
| Sep. 30 2024 | -1.94 | -1.93 | -2.18 | Missed | -13.1 |
| Jun. 30 2024 | -1.80 | -1.27 | -2.25 | Missed | -76.5 |
| Mar. 31 2024 | -1.05 | -1.50 | Missed | -42.9 | |
| Dec. 31 2023 | -1.27 | -1.27 | -0.75 | Beat | 41.2 |
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology